From April 7 to 9, 2023, the China Innovative Drug (Device) Medical Conference and CMAC Annual Meeting were successfully held at the Suzhou International Expo Center.

On April 1, the First National Medical Center for Infectious Diseases Infection Cooperation Forum & the First Oriental International Infection Week (Oriental ID Week), jointly organized by the National Medical Center for Infectious Diseases (NMCID), Fudan University Huashan Hospital, Shanghai Fudan University Education Development Foundation, and Shanghai Huashen Institute of Microbiology and Infection, were held in Shanghai.

Recently, the 2022 Shanghai Jing'an Park "Zhangjiang Star" Enterprise Cultivation Work Exchange Meeting was successfully held. The meeting introduced the "Zhangjiang Star" enterprise cultivation work and awarded plaques to the 2022 "Zhangjiang Star" enterprises. Shanghai UnionClin Co., Ltd.

Recently, Shanghai UnionClin Co., Ltd. signed a strategic cooperation agreement with Chongqing University Cancer Hospital regarding the development and application services of an innovative oncology drug clinical study system for the Phase I ward. 

On November 9, 2022, Shanghai Yingli Pharmaceutical Co., Ltd. (hereinafter referred to as "YL-Pharma") announced that the Class 1 anti-cancer new drug linperlisib has been approved for marketing by the China National Medical Products Administration (NMPA) for the treatment of relapsed/refractory (R/R) follicular lymphoma (FL), under the trade name Yin Tai Rui®.

To implement the innovation-driven development strategy, accelerate the construction of a science and technology innovation center with global influence, and promote the construction of enterprise technology centers in Jing'an District, the Jing'an District Commerce Committee organized the application and evaluation work for the 2022 Jing'an District Enterprise Technology Center.